It's a nice win for Merck. It will provide a nice floor for the stock going forward, and for all drug stocks, which will provide a nice lift to the overall market.
It's a nice win for Merck, ... It will provide a nice floor for the stock going forward, and for all drug stocks, which will provide a nice lift to the overall market.
The real concern here is 'stagflation' possibilities as slowing economic growth combines with higher inflation.
The Intel revenue warning provided further evidence of slowing growth in corporate earnings. Given that the market has already priced in this slow growth. downside from here should be pretty well muted for U.S. equities.